<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>SM-20220 (N-(aminoiminomethyl)-1-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1H-<z:chebi fb="0" ids="35581">indole</z:chebi>-2-<z:chebi fb="0" ids="23004,37622">carboxamide</z:chebi> <z:chebi fb="0" ids="25224">methanesulfonate</z:chebi>) is a <z:chebi fb="1" ids="29101">Na+</z:chebi>/H+ exchanger (NHE) inhibitor which has been shown to attenuate <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> in the rat transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> model </plain></SENT>
<SENT sid="1" pm="."><plain>However, to date, the effect of SM-20220 on <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> has not been examined </plain></SENT>
<SENT sid="2" pm="."><plain>The present experiments were designed to investigate these effects, using both transient and permanent middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion models in rats </plain></SENT>
<SENT sid="3" pm="."><plain>A dose of 1 mg/kg given intravenously 30 min after the <z:hpo ids='HP_0003674'>onset</z:hpo> of transient <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion reduced the infarcted area </plain></SENT>
<SENT sid="4" pm="."><plain>In the permanent <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion model, SM-20220 reduced the infarcted area when treatment was delayed for 5, 30 or 60 min after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The present results show that NHE has a crucial role in the pathogenesis of ischemic brain damage </plain></SENT>
<SENT sid="6" pm="."><plain>This NHE inhibitor may be useful for treating <z:hpo ids='HP_0001297'>stroke</z:hpo> because of its effectiveness with both forms of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and because of its postischemic administration </plain></SENT>
</text></document>